Vincent A. DiPippo

836 total citations
29 papers, 552 citations indexed

About

Vincent A. DiPippo is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Vincent A. DiPippo has authored 29 papers receiving a total of 552 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Radiology, Nuclear Medicine and Imaging, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Vincent A. DiPippo's work include Radiopharmaceutical Chemistry and Applications (16 papers), Prostate Cancer Treatment and Research (15 papers) and Cancer, Hypoxia, and Metabolism (7 papers). Vincent A. DiPippo is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (16 papers), Prostate Cancer Treatment and Research (15 papers) and Cancer, Hypoxia, and Metabolism (7 papers). Vincent A. DiPippo collaborates with scholars based in United States and Canada. Vincent A. DiPippo's co-authors include William C. Olson, C. Andrew Powers, Nancy Stambler, Joseph S. Dillon, Richard B. Noto, Camilo Jiménez, Lilja B. Sólnes, Bennett B. Chin, Daniel A. Pryma and Syed Mahmood and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and Cancer Research.

In The Last Decade

Vincent A. DiPippo

29 papers receiving 539 citations

Peers

Countries citing papers authored by Vincent A. DiPippo

Since Specialization

Citations

This map shows the geographic impact of Vincent A. DiPippo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent A. DiPippo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent A. DiPippo more than expected).

Fields of papers citing papers by Vincent A. DiPippo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent A. DiPippo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent A. DiPippo. The network helps show where Vincent A. DiPippo may publish in the future.

Co-authorship network of co-authors of Vincent A. DiPippo

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent A. DiPippo. A scholar is included among the top collaborators of Vincent A. DiPippo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent A. DiPippo. Vincent A. DiPippo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Changes in planned disease management after piflufolastat F¹⁸ PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. 2023 ·Journal of Clinical Oncology ·Frédéric Pouliot, Michael A. Gorin, Steven P. Rowe, Lawrence Saperstein, Béla Dénes, Vincent A. DiPippo, Nancy Stambler, Michael J. Morris, Barry A. Siegel	1
2	Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma 2022 ·Endocrine Related Cancer ·Camilo Jiménez, Bennett B. Chin, Richard B. Noto, Joseph S. Dillon, Lilja B. Sólnes, Nancy Stambler, Vincent A. DiPippo, Daniel A. Pryma	10
3	PD31-06 UPDATED LONG-TERM SURVIVAL AND SAFETY FROM A MULTI-CENTER, OPEN-LABEL, PIVOTAL PHASE 2 STUDY OF AZEDRA® IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA 2020 ·The Journal of Urology ·(unknown), Bennett B. Chin, Richard B. Noto, Joseph S. Dillon, Lilja B. Sólnes, Vincent A. DiPippo, Nancy Stambler, Vivien Wong, Daniel A. Pryma	1
4	SAT-163 Status at 10 Years: Long-Term Follow-Up for a Phase 2a Study of High-Specific-Activity (HSA) I 131 Iobenguane in Patients (Pts) with Relapsed/Refractory High-Risk Neuroblastoma 2020 ·Journal of the Endocrine Society ·Judith G. Villablanca, John M. Maris, Nancy Stambler, Duo Zhou, Vincent A. DiPippo, Katherine K. Matthay	2
5	Efficacy and Safety of High-Specific-Activity ¹³¹I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma 2018 ·Journal of Nuclear Medicine ·Daniel A. Pryma, Bennett B. Chin, Richard B. Noto, Joseph S. Dillon, Stephanie M. Perkins, Lilja B. Sólnes, Lale Kostakoğlu, Aldo N. Serafini, Miguel Hernandez Pampaloni, Jessica Jensen, Thomas Armor, Tess Lin, (unknown), Nancy Stambler, Stuart C. Apfel, Vincent A. DiPippo, Syed Mahmood, Vivien Wong, Camilo Jiménez	191
6	Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study. 2018 ·Journal of Clinical Oncology ·Daniel A. Pryma, Bennett B. Chin, Richard B. Noto, Joseph S. Dillon, Lilja B. Sólnes, (unknown), Nancy Stambler, Tess Lin, Vincent A. DiPippo, (unknown), Syed Mahmood, Vivien Wong, Camilo Jiménez	3
7	A prospective phase 2/3 multicenter study of ¹⁸F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY). 2018 ·Journal of Clinical Oncology ·Michael J. Morris, Peter R. Carroll, Stephan Probst, Frédéric Pouliot, Lawrence Saperstein, Barry A. Siegel, Ajjai Alva, Mark A. Preston, Akash Patnaik, Michael A. Gorin, Jeremy C. Durack, Melissa Nichols, Tess Lin, Thomas Strack, Vincent A. DiPippo, (unknown), Syed Mahmood, Vivien Wong, Kenneth J. Pienta	3
8	MP82-09 PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN PATIENTS (PTS) WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) FOLLOWING ABIRATERONE AND/OR ENZALUTAMIDE (ABI/ENZ): RESULTS FROM A PHASE 2 STUDY 2015 ·The Journal of Urology ·Daniel P. Petrylak, Nicholas J. Vogelzang, (unknown), Mark T. Fleming, David C. Smith, Leonard J. Appleman, Arif Hussain, Manuel Modiano, Parminder Singh, Scott T. Tagawa, Ira Gore, (unknown), (unknown), Oliver Sartor, Brad Somer, Raymond Wadlow, Neal D. Shore, Nancy Stambler, Vincent A. DiPippo, Robert J. Israel	3
9	Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer 2015 ·The Prostate ·Vincent A. DiPippo, Holly M. Nguyen, Lisha G. Brown, William C. Olson, Robert L. Vessella, Eva Corey	25
10	Expression of prostate-specific membrane antigen (PSMA) on circulating tumor cells (CTCs) in castration-resistant prostate cancer. 2014 ·Journal of Clinical Oncology ·(unknown), (unknown), Amanda Anderson, Dena Marrinucci, (unknown), Vincent A. DiPippo, William C. Olson	3
11	A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). 2014 ·Journal of Clinical Oncology ·Daniel P. Petrylak, David C. Smith, Leonard J. Appleman, Mark T. Fleming, Arif Hussain, Robert Dreicer, Oliver Sartor, Neal D. Shore, Nicholas J. Vogelzang, Hagop Youssoufian, Vincent A. DiPippo, Nancy Stambler, (unknown), Robert J. Israel	9
12	Efficacy studies of an antibody‐drug conjugate PSMA‐ADC in patient‐derived prostate cancer xenografts 2014 ·The Prostate ·Vincent A. DiPippo, William C. Olson, Holly M. Nguyen, Lisha G. Brown, Robert L. Vessella, Eva Corey	28
13	Antiandrogen modulation of prostate-specific membrane antigen (PSMA): Dynamics and synergy with PSMA-targeted therapy. 2013 ·Journal of Clinical Oncology ·Vincent A. DiPippo, (unknown), (unknown), (unknown), William C. Olson	6
14	The characterization of PPARα ligand drug action in an in vivo model by comprehensive differential gene expression profiling 2001 ·Functional & Integrative Genomics ·Bonnie E. Gould Rothberg, Scott S. Sundseth, Vincent A. DiPippo, Peter J. Brown, Deborah A. Winegar, (unknown), Suresh Shenoy, Jonathan M. Rothberg	14
15	Differential gene expression technologies for identifying surrogate markers of drug efficacy and toxicity 2000 ·Drug Discovery Today ·Joseph A. Rininger, Vincent A. DiPippo, (unknown)	22
16	Tamoxifen and ICI 182,780 Interactions with Thyroid Hormone in the Ovariectomized-Thyroidectomized Rat 1997 ·Journal of Pharmacology and Experimental Therapeutics ·Vincent A. DiPippo, C. Andrew Powers	15
17	Estradiol and tamoxifen interactions with thyroid hormone in the ovariectomized-thyroidectomized rat. 1995 ·Endocrinology ·Vincent A. DiPippo, Robert Lindsay, C. Andrew Powers	25
18	The antiproteinuric action of enalapril in stroke-prone spontaneously hypertensive rats is unrelated to alterations in urinary prostaglandins. 1992 ·Journal of Pharmacology and Experimental Therapeutics ·Charles T. Stier, Keyvan Mahboubi, Vincent A. DiPippo, Sherman D. Levine, Praveen Chander	16
19	Estrogen Induction of Growth Hormone in the Thyroidectomized Rat* 1991 ·Endocrinology ·Vincent A. DiPippo, C. Andrew Powers	12
20	Biological thiols elicit prolactin proteolysis by glandular kallikrein and permit regulation by biochemical pathways linked to redox control 1991 ·Biochemistry ·Mary Ann Hatala, Vincent A. DiPippo, C. Andrew Powers	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact